Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388. Demeter LM, et al. Among authors: hellmann ns. Clin Infect Dis. 2004 Aug 15;39(4):552-8. doi: 10.1086/422518. Epub 2004 Jul 30. Clin Infect Dis. 2004. PMID: 15356820 Clinical Trial.
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Swanstrom R, et al. J Infect Dis. 2004 Sep 1;190(5):886-93. doi: 10.1086/422692. Epub 2004 Jul 23. J Infect Dis. 2004. PMID: 15295692 Clinical Trial.
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Deeks SG, et al. Among authors: hellmann ns. J Infect Dis. 1999 Jun;179(6):1375-81. doi: 10.1086/314775. J Infect Dis. 1999. PMID: 10228057 Clinical Trial.
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R; California Collaborative Treatment Group #575 Team. Kemper CA, et al. Among authors: hellmann ns. AIDS. 2001 Mar 30;15(5):609-15. doi: 10.1097/00002030-200103300-00010. AIDS. 2001. PMID: 11316998
Antiretroviral resistance during successful therapy of HIV type 1 infection.
Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E, Gunthard HF, Sutton L, Savara A, Petropoulos CJ, Hellmann N, Walker BD, Richman DD, Siliciano R, D'Aquila RT. Martinez-Picado J, et al. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10948-53. doi: 10.1073/pnas.97.20.10948. Proc Natl Acad Sci U S A. 2000. PMID: 11005867 Free PMC article.
56 results